Antigen presenting cell targeted cancer vaccines
AssigneeBbaylor Research Institute
InventorsGerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon OH
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
Claims21
-58. (canceled)
A method for inducing cytotoxic T-cell response against tumor cells in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising a fusion protein, wherein the fusion protein comprises an anti-CD40 antibody or portion thereof linked to one or more cancer antigens.
A method for treating cancer in a subject, the method comprising administering to the subject an effective amount of a composition comprising a fusion protein, wherein the fusion protein comprises an anti-CD40 antibody or portion thereof linked to one or more cancer antigens.
A composition comprising a fusion protein, wherein the fusion protein comprises an anti-CD40 antibody or portion thereof linked to one or more cancer antigens.
Dependencies are inferred from the claim text.